S&P 500   4,109.31
DOW   33,274.15
QQQ   320.93
Mullen Automotive Makes Deliveries; Short-Squeeze Possible
"Prepare for Five Years of Famine" (Ad)
Schwab’s Drop This Week Could Be The Opening Of The Year (Again)
What is a Gold IRA, and is it a Viable Investment?
"Prepare for Five Years of Famine" (Ad)
Closing prices for crude oil, gold and other commodities
Walmart Shares Jump on Evercore Analyst Upgrade 
The Market Crash Shield is A.I. (Ad)pixel
Is Braze, Inc Ready To Rocket Higher? 
Can Frontline Maintain This Momentum?
S&P 500   4,109.31
DOW   33,274.15
QQQ   320.93
Mullen Automotive Makes Deliveries; Short-Squeeze Possible
"Prepare for Five Years of Famine" (Ad)
Schwab’s Drop This Week Could Be The Opening Of The Year (Again)
What is a Gold IRA, and is it a Viable Investment?
"Prepare for Five Years of Famine" (Ad)
Closing prices for crude oil, gold and other commodities
Walmart Shares Jump on Evercore Analyst Upgrade 
The Market Crash Shield is A.I. (Ad)pixel
Is Braze, Inc Ready To Rocket Higher? 
Can Frontline Maintain This Momentum?
S&P 500   4,109.31
DOW   33,274.15
QQQ   320.93
Mullen Automotive Makes Deliveries; Short-Squeeze Possible
"Prepare for Five Years of Famine" (Ad)
Schwab’s Drop This Week Could Be The Opening Of The Year (Again)
What is a Gold IRA, and is it a Viable Investment?
"Prepare for Five Years of Famine" (Ad)
Closing prices for crude oil, gold and other commodities
Walmart Shares Jump on Evercore Analyst Upgrade 
The Market Crash Shield is A.I. (Ad)pixel
Is Braze, Inc Ready To Rocket Higher? 
Can Frontline Maintain This Momentum?
S&P 500   4,109.31
DOW   33,274.15
QQQ   320.93
Mullen Automotive Makes Deliveries; Short-Squeeze Possible
"Prepare for Five Years of Famine" (Ad)
Schwab’s Drop This Week Could Be The Opening Of The Year (Again)
What is a Gold IRA, and is it a Viable Investment?
"Prepare for Five Years of Famine" (Ad)
Closing prices for crude oil, gold and other commodities
Walmart Shares Jump on Evercore Analyst Upgrade 
The Market Crash Shield is A.I. (Ad)pixel
Is Braze, Inc Ready To Rocket Higher? 
Can Frontline Maintain This Momentum?
NASDAQ:PCRX

Pacira BioSciences - PCRX Stock Forecast, Price & News

$40.81
+0.63 (+1.57%)
(As of 03/31/2023 12:00 AM ET)
Add
Compare
Today's Range
$40.36
$40.92
50-Day Range
$37.32
$43.38
52-Week Range
$35.35
$82.16
Volume
306,182 shs
Average Volume
523,476 shs
Market Capitalization
$1.88 billion
P/E Ratio
131.65
Dividend Yield
N/A
Price Target
$64.36

Pacira BioSciences MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.86 Rating Score
Upside/​Downside
57.7% Upside
$64.36 Price Target
Short Interest
Healthy
7.31% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.42
Upright™ Environmental Score
News Sentiment
0.55mentions of Pacira BioSciences in the last 14 days
Based on 9 Articles This Week
Insider Trading
Selling Shares
$20,917 Sold Last Quarter
Proj. Earnings Growth
56.04%
From $2.73 to $4.26 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.84 out of 5 stars

Medical Sector

49th out of 1,004 stocks

Pharmaceutical Preparations Industry

13th out of 489 stocks


PCRX stock logo

About Pacira BioSciences (NASDAQ:PCRX) Stock

Pacira Biosciences, Inc. is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients' journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.

Receive PCRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Pacira BioSciences and its competitors with MarketBeat's FREE daily newsletter.

PCRX Stock News Headlines

Pacira's SNDA For Extension Of Exparel Label Accepted By FDA
The "King Of Quants" sees 10X potential...
Eric Fry believes he just discovered America's next "Wealth Supercluster" and it's forming in the place you'd least expect. Investors are already flocking there for a chance at 1,000%+ returns. Here's how you could join them before it's too late...
BREAKING: Tiny biotech successfully treats blindness
There's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.
Analyst Expectations for Pacira BioSciences's Future
Q4 2022 Pacira Biosciences Inc Earnings Call
Earnings Preview For Pacira BioSciences
Pacira Pharmaceuticals, Inc. (PCRX)
Wedbush Keeps Their Buy Rating on Pacira Pharmaceuticals (PCRX)
See More Headlines
Receive PCRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Pacira BioSciences and its competitors with MarketBeat's FREE daily newsletter.

PCRX Company Calendar

Last Earnings
2/28/2023
Today
4/01/2023
Next Earnings (Estimated)
5/03/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceuticals
Sector
Medical
Current Symbol
NASDAQ:PCRX
CUSIP
69512710
Employees
697
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$64.36
High Stock Price Forecast
$80.00
Low Stock Price Forecast
$50.00
Forecasted Upside/Downside
+57.7%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.86
Research Coverage
7 Analysts

Profitability

Net Income
$15.91 million
Pretax Margin
1.99%

Debt

Sales & Book Value

Annual Sales
$666.82 million
Cash Flow
$4.02 per share
Book Value
$16.89 per share

Miscellaneous

Free Float
43,149,000
Market Cap
$1.88 billion
Optionable
Optionable
Beta
0.77

Key Executives

  • David M. StackDavid M. Stack
    Chairman & Chief Executive Officer
  • Daryl J. Gaugler
    Chief Operating Officer
  • Charles A. ReinhartCharles A. Reinhart
    Chief Financial Officer
  • Roy WinstonRoy Winston
    Chief Medical Officer
  • Charles Anthony Laranjeira
    Chief Technical Officer













PCRX Stock - Frequently Asked Questions

Should I buy or sell Pacira BioSciences stock right now?

7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Pacira BioSciences in the last year. There are currently 1 hold rating and 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" PCRX shares.
View PCRX analyst ratings
or view top-rated stocks.

What is Pacira BioSciences' stock price forecast for 2023?

7 analysts have issued 12-month target prices for Pacira BioSciences' shares. Their PCRX share price forecasts range from $50.00 to $80.00. On average, they expect the company's stock price to reach $64.36 in the next year. This suggests a possible upside of 57.7% from the stock's current price.
View analysts price targets for PCRX
or view top-rated stocks among Wall Street analysts.

How have PCRX shares performed in 2023?

Pacira BioSciences' stock was trading at $38.61 on January 1st, 2023. Since then, PCRX stock has increased by 5.7% and is now trading at $40.81.
View the best growth stocks for 2023 here
.

When is Pacira BioSciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 3rd 2023.
View our PCRX earnings forecast
.

How were Pacira BioSciences' earnings last quarter?

Pacira BioSciences, Inc. (NASDAQ:PCRX) issued its quarterly earnings data on Tuesday, February, 28th. The company reported $0.60 EPS for the quarter, missing the consensus estimate of $0.71 by $0.11. The firm had revenue of $171.96 million for the quarter, compared to analyst estimates of $174.12 million. Pacira BioSciences had a trailing twelve-month return on equity of 11.09% and a net margin of 2.39%.

What guidance has Pacira BioSciences issued on next quarter's earnings?

Pacira BioSciences issued an update on its FY22 earnings guidance on Thursday, January, 5th. The company provided earnings per share (EPS) guidance of at least $2.50 for the period, compared to the consensus EPS estimate of $2.64. The company issued revenue guidance of $666.8 million, compared to the consensus revenue estimate of $676.64 million.

What is Dave Stack's approval rating as Pacira BioSciences' CEO?

54 employees have rated Pacira BioSciences Chief Executive Officer Dave Stack on Glassdoor.com. Dave Stack has an approval rating of 45% among the company's employees. This puts Dave Stack in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Pacira BioSciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Pacira BioSciences investors own include Gilead Sciences (GILD), NVIDIA (NVDA), Micron Technology (MU), ACADIA Pharmaceuticals (ACAD), Skyworks Solutions (SWKS), AbbVie (ABBV), Pfizer (PFE), QUALCOMM (QCOM), Exelixis (EXEL) and Tesla (TSLA).

What is Pacira BioSciences' stock symbol?

Pacira BioSciences trades on the NASDAQ under the ticker symbol "PCRX."

How do I buy shares of Pacira BioSciences?

Shares of PCRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Pacira BioSciences' stock price today?

One share of PCRX stock can currently be purchased for approximately $40.81.

How much money does Pacira BioSciences make?

Pacira BioSciences (NASDAQ:PCRX) has a market capitalization of $1.88 billion and generates $666.82 million in revenue each year. The company earns $15.91 million in net income (profit) each year or $0.31 on an earnings per share basis.

How many employees does Pacira BioSciences have?

The company employs 697 workers across the globe.

How can I contact Pacira BioSciences?

Pacira BioSciences' mailing address is 5 SYLVAN WAY SUITE 300, PARSIPPANY NJ, 07054. The official website for the company is www.pacira.com. The company can be reached via phone at (813) 553-6680, via email at susan.mesco@pacira.com, or via fax at 302-655-5049.

This page (NASDAQ:PCRX) was last updated on 4/1/2023 by MarketBeat.com Staff